Full Press Release Details
NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) -- viaInvestorWire— Soligenix Inc. (NASDAQ: SNGX) today announces its placement in an editorial published byNetworkNewsWire("NNW"), one of 70+ brands within theDynamic Brand Portfolio@IBN(InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.
To view the full publication, “Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators,” please visit:https://nnw.fm/QCrhc.
As the American population gets older, chronic and rare diseases are becoming a significant healthcare issue, particularly for older adults. The aging population's increasing life expectancy also leads to more complex healthcare needs, especially for conditions that are both chronic and difficult to diagnose. Many of these rare conditions lack FDA-approved treatments, and their symptoms in seniors are frequently mistaken for normal signs of aging, causing diagnostic delays that can last for years. There are more than 30 million Americans who have a rare disease, so there is a growing need for accurate diagnoses and effective treatments.
The Trump administration's "Make America Healthy Again" initiatives have highlighted this problem and focused on improving access to treatments and speeding up medical innovation. Soligenix Inc. (NASDAQ: SNGX) is working to advance this mission with its HyBryte(TM) platform, a new therapy for cutaneous T-cell lymphoma (CTCL), a rare form of skin cancer that largely impacts older adults. The company has successfully established U.S.-based manufacturing for HyBryte's active ingredient, demonstrating the kind of domestic innovation that can significantly help this underserved patient group.
AboutSoligenix Inc.
Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Its Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte(TM) (“SGX301” or synthetic hypericin) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (“CTCL”). With successful completion of the second Phase 3 study, regulatory approvals will be sought to support potential commercialization worldwide. Development programs in this business segment also include expansion of synthetic hypericin (“SGX302”) into psoriasis, the company’s first-in-class innate defense regulator (“IDR”) technology, dusquetide (“SGX942”) for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer, and (“SGX945”) in Behçet’s disease.
The company’s Public Health Solutions business segment includes development programs for RiVax(R), its ricin toxin vaccine candidate, as well as its vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax(TM), the company’s vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2). The development of Soligenix’s vaccine programs incorporates the use of its proprietary heat stabilization platform technology, known as ThermoVax(R). To date, this business segment has been supported with government grants and contract funding from the National Institute of Allergy and Infectious Diseases (“NIAID”), the Defense Threat Reduction Agency (“DTRA”) and the Biomedical Advanced Research and Development Authority (“BARDA”).
For further information, visit the company’s website atwww.Soligenix.com.
NOTE TO INVESTORS:The latest news and updates relating to SNGX are available in the company’s newsroom athttps://ibn.fm/SNGX
About NetworkNewsWire
NetworkNewsWire(“NNW”) is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 60+ brands within theDynamic Brand Portfolio@IBNthat delivers:(1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries;(2) article andeditorial syndication to 5,000+ outlets;(3)press release enhancementto ensure maximum impact;(4)social media distributionvia IBN to millions of social media followers;and (5) a full array of tailoredcorporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled recognition and brand awareness. NNW is where breaking news, insightful content and actionable information converge.
For more information, please visithttps://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished:https://www.NetworkNewsWire.com/Disclaimer
NetworkNewsWireNew York, NYwww.NetworkNewsWire.com212.418.1217 OfficeEditor@NetworkNewsWire.com
NetworkNewsWire is powered byIBN